The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic factors for progression-free and overall survival in patients with advanced GIST treated with standard-dose imatinib (IM): Results from the BFR14 phase III trial of the French Sarcoma Group.
F. Bertucci
No relevant relationships to disclose
J. Blay
Consultant or Advisory Role - GlaxoSmithKline; Novartis; PharmaMar; Roche
Honoraria - Bayer; Novartis; PharmaMar; Roche
I. L. Ray-Coquard
Consultant or Advisory Role - Novartis; PharmaMar; Roche
Honoraria - Novartis; PharmaMar; Roche
B. Bui Nguyen
No relevant relationships to disclose
A. Adenis
No relevant relationships to disclose
M. Rios
No relevant relationships to disclose
F. Duffaud
No relevant relationships to disclose
D. Cupissol
No relevant relationships to disclose
C. Chevreau
No relevant relationships to disclose
E. Bompas
No relevant relationships to disclose
A. Cioffi
No relevant relationships to disclose
L. Nehal
No relevant relationships to disclose
D. Perol
No relevant relationships to disclose
A. Le Cesne
Consultant or Advisory Role - Novartis; PharmaMar
Honoraria - Novartis; Pfizer; PharmaMar